Skip to main content Skip to main navigation menu Skip to site footer

The role of Neurotrophin 3 (NT-3) on neural plasticity in depression: a literature review

  • Hamzah Shatri ,
  • Muhammad Pranandi ,
  • Yanuar Ardani ,
  • Irman Firmansyah ,
  • Edward Faisal ,
  • Rudi Putranto ,


Background: Major Depressive Disorder (MDD) is a pervasive global health concern characterized by complex interactions between genetic and environmental factors, resulting in structural and functional alterations within the brain. This abstract explores the involvement of neurotrophin-3 (NT-3) in MDD, shedding light on its potential as a therapeutic target. Neuroanatomical evidence implicates brain regions like the amygdala, hippocampus, prefrontal cortex, and ventral striatum in MDD pathology, with aberrant synaptic plasticity and neurogenesis playing a crucial role.

Methods: We conducted a review using a systematic search of MEDLINE. The results of the studies that match the search criteria are then analyzed using a narrative synthesis to include in the literature review.

Results: There are four known brain regions and neurocircuits that are involved in depression, which are amygdala, hippocampus, prefrontal cortex, and ventral striatum. NT-3, a member of the neurotrophin family, has emerged as a critical modulator of depressive processes, whereas NT-3 influences monoamine neurotransmitters, serotonin, and noradrenaline while also regulating synaptic plasticity, neurogenesis, brain-derived neurotrophic factor signaling, and the hypothalamic-pituitary-adrenal (HPA) axis.

Conclusion: NT-3 emerges as a promising therapeutic target for MDD, with multifaceted effects on neurotransmitters, synaptic plasticity, neurogenesis, and the HPA axis. However, further preclinical and clinical studies are needed to comprehensively evaluate its potential in managing mood disorders.


  1. Xue Y, Liang H, Yang R, Deng K, Tang M, Zhang M. The role of pro-and mature neurotrophins in the depression. Behavioural Brain Research. 2021;404(1):113162.
  2. Levy MJ, Boulle F, Steinbusch HW, van den Hove DL, Kenis G, Lanfumey L. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology. 2018;235(8):2195-2220.
  3. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002;34(1):13-25.
  4. Phillips C. Brain-derived neurotrophic factor, depression, and physical activity: making the neuroplastic connection. Neural plasticity. 2017;1(1):1-18.
  5. de Miranda AS, de Barros JL, Teixeira AL. Is neurotrophin-3 (NT-3): a potential therapeutic target for depression and anxiety?. Expert Opinion on Therapeutic Targets. 2020;24(12):1225-1238.
  6. Jiang C, Salton S. The role of neurotrophins in major depressive disorder. Translational neuroscience. 2013;4(1):46-58.
  7. Cramer SC, Sur M, Dobkin BH, O'Brien C, Sanger TD, Trojanowski JQ, et al. Harnessing neuroplasticity for clinical applications. Brain. 2011;134(6):1591-1609.
  8. Castrén E, Hen R. Neuronal plasticity and antidepressant actions. Trends in neurosciences. 2013;36(5):259-267.
  9. Kempton MJ, Salvador Z, Munafo MR, Geddes JR, Simmons A, Frangou S, et al. Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bi- polar disorder. Arch Gen Psychiatry. 2021;68(1):675–690
  10. Paizanis E, Renoir T, Lelievre V, Saurini F, Melfort M, Gabriel C, et al. Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor- impaired mice. Int J Neuropsychopharmacol. 2010;13(1):759–774.
  11. Benarroch EE. Brain-derived neurotrophic factor: Regulation, effects, and potential clinical relevance. Neurology. 2015;84(16):1693-704.
  12. Pae CU, Marks DM, Han C, Patkar AA, Steffens D. Does neurotropin-3 have a therapeutic implication in major depression?. International Journal of Neuroscience. 2008;118(11):1515-1522.
  13. Yang T, Nie Z, Shu H, Kuang Y, Chen X, Cheng J, et al. The role of BDNF on neural plasticity in depression. Frontiers in cellular neuroscience. 2020;15(1):14:82.
  14. Muliarta M, Tirtayasa K, Prabawa PY, Wiryadana KA. Tamarillo Consumption Associated with Increased Acetylcholinesterase Activity and Improved Oxidative Stress Markers in Farmers Exposed to Daily Pesticide-related Activities in Baturiti, Bali, Indonesia. Open Access Macedonian Journal of Medical Sciences. 2020;8(E): 244-250.
  15. Silakarma D, Sudewi AAR. The role of brain-derived neurotrophic factor (BDNF) in cognitive functions. Bali Medical Journal. 2019;8(2):518–525.
  16. Widodo J, Asadul A, Wijaya A, Lawrence G. Correlation between Nerve Growth Factor (NGF) with Brain Derived Neurotropic Factor (BDNF) in Ischemic Stroke Patient. Bali Medical Journal. 2016;5(2):202–204.
  17. Pramana IBP, Oka AAG, Astawa INM, Mahadewa TGB. Adipose-Derived Stem Cells (ADSCs): a review article. Bali Medical Journal. 2021;10(3):881–886.

How to Cite

Shatri, H., Pranandi, M., Ardani, Y., Firmansyah, I., Faisal, E., & Putranto, R. (2023). The role of Neurotrophin 3 (NT-3) on neural plasticity in depression: a literature review. Intisari Sains Medis, 14(3), 1103–1108.